Generic Name and Formulations:
Methenamine hippurate 1g; tabs; contains tartrazine.
Indications for HIPREX:
Prophylaxis and suppression of recurrent UTIs.
1g twice daily.
<6yrs: not recommended. ≥6yrs: 0.5–1g twice daily.
Renal or severe hepatic insufficiency. Severe dehydration.
Maintain acid urine. Monitor therapy and liver function with repeated urine cultures. Aspirin allergy. Elderly. Pregnancy.
Sulfonamides precipitate with formaldehyde in urine; avoid concomitant use.
Nausea, dysuria, rash, bladder irritation, albuminuria, hematuria, elevated transaminases.
Clinical Pain Advisor Articles
- Radiofrequency Denervation Efficacious in Treating Thoracic Zygapophyseal Joint Pain
- Prescribed Opioids Difficulties Scale Effective for Assessing Concerns of Patients With Chronic Pain
- Predictors of Opioid Overdose in High-Risk Users
- Optimal Strategies for Opioid Weaning After Ambulatory Surgery
- Emergency Physicians Offer Recommendations for Identifying and Managing Opioid Use Disorder
- Consensus Guidelines for the Use of Intravenous Ketamine for Chronic Pain
- Pain Societies Issue Guidelines on Use of Ketamine for the Management of Acute Pain
- Labor Epidural Analgesia Linked to Reduced Likelihood of Successful Breastfeeding
- Novel Oral Treatment Safe, Effective for Migraine Headache Relief
- DFN-02 Nasal Spray Safe, Effective for Acute Treatment of Episodic Migraine
- Higher PainDETECT Scores, Neuropathic Pain Preoperatively May Increase Risk for Chronic Pain Post-TKR
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Erenumab Reduces Monthly Migraine Days in Patients With Treatment-Resistant Migraine
- Government and Industry Lead the Way in Funding USPSTF Systematic Reviews
- Communication-Based Intervention Increases Goals-of-Care Discussions Between Physicians, Patients With Serious Illness